REGENXBIO closes up to $250M royalty bond with HCRx; $150M funded, cash runway into early 2027

REGENXBIO Inc.

Received $150M at closing; up to $250M total via three tranches, including $50M contingent on Zolgensma sales threshold by Apr 2027.
Royalty bond bears interest at 9.75% + 3-month SOFR (4.25% floor); repayment solely from royalties on Zolgensma, RGX-121, RGX-111, and NAV platform licensees.
Issued HCRx warrant for 268,096 shares at $14.92 (100% premium to 30-day VWAP), exercisable for 10 years.
Extends expected cash runway into early 2027, funding late-stage programs including RGX-121, RGX-202, and ABBV-RGX-314.
Retains future non-dilutive sources: potential Priority Review Voucher for RGX-121 and milestones from AbbVie and Nippon Shinyaku.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.